Evidence mapPaperPMID 41348235Full record

ArticleMolecular genetics and genomics : MGG2025

Resveratrol mitigates diabetes-induced cardiac dysfunction via SIRT1/PPAR-α/PGC-1 pathway.

Ruirui Fu, Ju Hao

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular genetics and genomics : MGG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ruirui FuDepartment of Geriatric, The Third Hospital of Hebei Medical University, No. 139 Ziqianlu Road, Shijiazhuang, 050051, Hebei, China.
Ju HaoDepartment of Geriatric, The Third Hospital of Hebei Medical University, No. 139 Ziqianlu Road, Shijiazhuang, 050051, Hebei, China. Haoju2012@163.com.ORCID http://orcid.org/0009-0005-1476-1948

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic cardiomyopathy (DCM) significantly contributes to cardiovascular complications in diabetes. This study investigated the protective effects of Resveratrol (RES) in combination with evidence-based nursing on DCM and the underlying molecular mechanisms. Eighty elderly patients with type 2 diabetes mellitus (T2DM) and DCM were randomly assigned to a control group or an RES group. The RES group received RES (800 mg/day) along with evidence-based nursing, while the control group received a placebo with nursing care for six months. Clinical indicators, including glucose and lipid metabolism, lactate dehydrogenase (LDH) activity, inflammatory markers, and cardiac function parameters, were evaluated. Additionally, T2DM rat models were used to examine oxidative stress, cells proliferation, fats accumulation, mitochondrial dysfunction, apoptosis and autophagy, while high glucose (HG)-induced H9C2 myocardial cells were used to investigate cellular mechanisms involving the SIRT1/PPAR-α/PGC-1 pathway. RES combined with evidence-based nursing improved glucose and lipid metabolism, reduced LDH activity, decreased inflammatory markers (TNF-α, IL-6), and enhanced cardiac function in T2DM patients with DCM. In rats, RES restored left ventricular ejection fraction (LVEF) and fractional shortening (LVFS) while reducing myocardial apoptosis with lower Bax and cleaved caspase-3 levels and higher Bcl-2 expression, reduced fibrosis and fat accumulation. Additionally, RES alleviated oxidative stress by decreasing reactive oxygen species (ROS) and malondialdehyde (MDA) levels, suppressed myocardial apoptosis, improved mitochondrial function while increasing ATP and superoxide dismutase (SOD) activity as well as enhancing autophagy. SIRT1 inhibitor (EX527) injections in rats reversed the beneficial effects of RES. In HG-treated H9C2 cells, RES improved cell viability, reduced apoptosis, alleviated oxidative stress and enhanced autophagy. RES ameliorates DCM through SIRT1/PPAR-α/PGC-1 signaling pathway in rats and improves efficacy of elderly DM patients in combination with evidence-based care.

Indexed as

Diabetes Mellitus, Type 2Diabetic CardiomyopathiesPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPAR alphaResveratrolSirtuin 1AgedAnimalsApoptosisDiabetes Mellitus, ExperimentalFemaleHumansMaleMiddle AgedMyocytes, CardiacOxidative StressPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPAR alphaPPARGC1A protein, humanResveratrolSIRT1 protein, humanSirtuin 1Cardiac dysfunctionDiabetesPPAR-α/PGC-1 signaling pathwayResveratrolSIRT1

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.